Digene
This article was originally published in The Gray Sheet
Executive Summary
Planned secondary offering of 2.5 mil. shares is withdrawn by the company March 19. Adverse market conditions are cited. The Gaithersburg, Maryland-based manufacturer of DNA tests for human papillomavirus notes that despite the move, "the company has a strong balance sheet and the financial resources to continue the execution of its growth strategy." Cash on hand stood at approximately $6.6 mil. as of Dec. 31. Second-quarter (ended Dec. 31) revenues were up 48% to $7.8 mil. A net loss of $1.6 mil. for the quarter was roughly even with that of the comparable quarter last year. Digene expects to file a PMA supplement by year-end for a primary screening indication of its HybridCapture 2 HPV test (1"The Gray Sheet" Feb. 26, 2001, p. 15)
You may also be interested in...
NCI HPV Trial Data Re-Evaluated By Digene To Support PMA Supplement
Digene will reanalyze clinical data and specimens from a 23,702-patient trial in Portland, Oregon, prior to seeking a primary screening indication for its HybridCapture 2 HPV test. The Gaithersburg, Maryland firm expects to file a PMA supplement by year-end.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.